Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HCAT
HOLDHealth Catalyst, Inc. · Healthcare · United States · $154M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Health Catalyst, Inc. is a leading provider of data and analytics technology and services to healthcare organizations. The company's proprietary Data Operating System (DOS) integrates clinical, financial, and operational data to drive measurable clinical improvements. Its competitive moat is sustained by high customer switching costs and a deep library of healthcare-specific analytics applications.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 276.2M | 295.9M | 306.6M | 311.1M | 4.0% | 302.5M | 266.9M | 250.3M | -10.3% |
| EPS | -2.56 | -2.09 | -1.15 | -2.55 | — | -3.58 | — | — | — |
| Shares | 55.3M | 58.3M | 64.0M | 72.0M | +30.3% | 73.9M | — | — | — |
| Debt | 248.0M | 249.1M | 402.3M | 171.2M | -11.6% | 170.6M | — | — | — |
| Equity | 425.0M | 366.9M | 365.2M | 245.8M | -16.7% | — | — | — | — |
| Op CF | -35.3M | -33.1M | 14.6M | 0.7M | -95.0% | 19.0M | — | — | — |
| Inv CF | -39.0M | 20.3M | -22.9M | 36.2M | — | — | — | — | — |
| Fin CF | -2.6M | 2.7M | 151.7M | -235.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HCAT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HCAT | Health Catalyst, Inc.(you) | $154M | 40 | HOLD |
| LFMD | LifeMD, Inc. | $179M | 33 | SELL |
| DH | Definitive Healthcare Corp. | $72M | 40 | HOLD |
| NURS.V | Hydreight Technologies Inc. | $167M | 55 | HOLD |
| CTEV | Claritev Corporation | $368M | 39 | HOLD |
| EVH | Evolent Health, Inc. | $475M | 40 | HOLD |
| CARL | Carlsmed, Inc. | $294M | 25 | SELL |
| AMWL | American Well Corporation | $181M | 68 | BUY |
| PHR | Phreesia, Inc. | $632M | 47 | HOLD |
| OPRX | OptimizeRx Corporation | $117M | 77 | BUY |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%